NCT00373490View on ClinicalTrials.gov

A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048)

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
Tumors
Interventions
DRUG

Vorinostat

600 mg daily (300 mg twice daily \[b.i.d.\]) for 3 consecutive days followed by 4 days of rest.

DRUG

Vorinostat

400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00373490 - A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048) | Biotech Hunter | Biotech Hunter